Final Program Programme FINAL NOW AVAILABLE!
Total Page:16
File Type:pdf, Size:1020Kb
Final Program Programme FINAL www.cano-acio.ca NOW AVAILABLE! In combination with dexamethasone, One-capsule-per- chemotherapy-cycle Akynzeo® Akynzeo® (netupitant/palonosetron) in combination with dexamethasone, is indicated for once-per-cycle treatment in adult patients for: • Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy • Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone Consult the product monograph at www.purdue.ca/en/products/Akynzeo-PM for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The product monograph is also available by calling Purdue Pharma at 1-800-387-5349. Akynzeo® is a trademark of Helsinn Healthcare used under license by Purdue Pharma. Distributed under license of Helsinn Healthcare SA, Switzerland. © 2018 Purdue Pharma. All rights reserved. CA-NTP-0443E PUR17AK023 Akynzeo Journal Ad_E2.indd 1 2018-05-25 1:42 PM vx160026_13_01E_JAN_Corporate_Ads_OncologyOUTLINE_FONTS.indd 1 2016-09-17 11:51 AM Kyprolis Journal Ad_CANO 2018 hires.pdf 1 5/29/18 3:29 PM When multiple myeloma relapses Push back with the power of Kyprolis® Kyprolis® (carfilzomib), in combination with either lenalidomide and dexamethasone or dexamethasone alone, is indicated for the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy.1 C Overall response rate M for KRd vs Rd was 87% vs 67% Y (p<0.001; secondary endpoint)*1, 2 CM Clinical use Posterior reversible encephalopathy syndrome (PRES): • Dyspnea; withhold Kyprolis® until grade 3 or 4 dyspnea MY Clinical effectiveness of KRd has not been established in patients cases reported. Withhold Kyprolis® if PRES is suspected; resolves or returns to baseline with renal impairment (CrCL <50 mL/min). Clinical effectiveness evaluate by imaging. Discontinue if confirmed. • Monitor blood pressure, complete blood cell counts (CBC), CY blood chemistry, and electrolytes at baseline and throughout of KRd or Kd has not been established in patients who progressed Pulmonary toxicities: acute respiratory distress syndrome during prior bortezomib therapy. The incidence of certain adverse treatment and liver enzymes regularly, regardless of baseline CMY (ARDS), acute respiratory failure, acute diffuse infiltrative events (including cardiac failure) in clinical trials was higher for pulmonary disease, and pulmonary hypertension; fatal outcomes values, and modify based on toxicity K • Females of reproductive potential should use patients who were ≥65 years (vs <65 years). reported. Withhold Kyprolis® until these effects resolve or return The safety and effectiveness of Kyprolis® in pediatric patients contraception during and for 30 days after therapy to baseline. have not been established. • Males should use contraception during and for 90 days after therapy Most serious warnings and precautions Other relevant warnings and precautions • Kyprolis® should not be administered while breastfeeding Duration of infusion: Kyprolis® dosed at 56 mg/m2 must be • Not indicated as monotherapy for relapsed and ® 2 refractory multiple myeloma infused over 30 minutes; Kyprolis dosed at 27 mg/m must be For more information ® • Dose reduction by 25% required in patients with mild or infused over ≥ 10 minutes. Kyprolis administered with a short Consult the Product Monograph at moderate hepatic impairment infusion time, without pre-medication with dexamethasone and www.amgen.ca/Kyprolis_PM.pdf for important information • Not evaluated in patients with cardiac impairment adequate hydration, or without stepped up dosing, may not be relating to adverse reactions, drug interactions, and dosing and (NYHA class III and IV heart failure); patients with well tolerated. administration which has not been discussed in this piece. The LVEF < 40% were not eligible for the ENDEAVOR study Cardiac toxicities: new or worsening cardiac failure and Product Monograph is also available by calling Amgen Medical myocardial ischemia and infarction; increased risk of cardiovas- • Infusion reactions, including life-threatening reactions, immediately or within 24 hours of dose; ensure Information at 1-866-502-6436. cular events (eg., cardiac failure) in elderly (≥75 years); fatal appropriate hydration and dexamethasone administration outcomes reported. Monitor and adjust fluid volume as clinically *ASPIRE: randomized, open-label, multicentre, phase 3 study conducted in 792 prior to treatment indicated. Withhold Kyprolis® until grade 3 or 4 cardiac events patients with relapsed multiple myeloma who had received 1 to 3 prior lines of • Tumour lysis syndrome; fatal outcomes reported. Ensure therapy. Patients were randomized 1:1 to receive KRd (n=396) or Rd (n=396) in resolve. 28-day cycles. KRd was administered for a maximum of 18 cycles unless appropriate hydration. Monitor serum electrolytes; discontinued early for disease progression or unacceptable toxicity. Rd could Venous thrombosis: including deep vein thrombosis and consider uric acid lowering drugs for patients at high risk continue until progression or unacceptable toxicity. The primary endpoint, PFS, was determined by an Independent Review Committee using standard objective pulmonary embolism; fatal outcomes reported. Monitor for signs • QT interval prolongation International Myeloma Working Group/European Blood and Marrow and symptoms. Thromboprophylaxis is recommended. • Hypertension, including hypertensive crisis and Transplantation response criteria. Important exclusion criteria included creatinine clearance <50 mL/min, disease progression on a bortezomib-containing regimen, Hemorrhage: including gastrointestinal, intracranial, and hypertensive emergency; fatal outcomes reported. progression during the first three months of Rd treatment, or progression at any time during Rd treatment if this was the most recent therapy.1,2 pulmonary hemorrhage; fatal outcomes reported. Hypertension should be well-controlled prior to treatment initiation and evaluated throughout treament; withhold Thrombotic microangiopathy: including thrombotic Kyprolis® for hypertensive crisis and hypertensive CrCL = creatinine clearance; Kd = Kyprolis® + dexamethasone; thrombocytopenic purpura (TTP) and hemolytic uremic syndrome KRd = Kyprolis® + lenalidomide + dexamethasone; emergency, and consider dose reductions when LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; (HUS); fatal outcomes reported. Monitor for signs and symptoms. resuming treatment PFS = progression-free survival; Rd = lenalidomide + dexamethasone ® Withhold Kyprolis if TTP/HUS is suspected; discontinue if • Thrombocytopenia; monitor platelet counts frequently confirmed. and reduce or withhold Kyprolis® as appropriate Hepatic failure: fatal cases reported. Monitor liver enzymes • Acute renal failure; monitor renal function. Reduce, (ALT, AST) and bilirubin and reduce or withhold therapy as withhold or discontinue Kyprolis® as appropriate appropriate. • Limited data in patients with renal impairment (CrCL <50 mL/min), Kyprolis® should be administered after dialysis procedure, if applicable 1. Kyprolis® Product Monograph. Amgen Canada Inc. July 2017. 2. Stewart AK, et al. N Engl J Med. 2015; 372: 142-152. Kyprolis® is a registered trademark of Onyx Pharmaceuticals, Inc.,used herein with permission. ©2018 Amgen Canada Inc. All rights reserved. WHY WE INVENT At Merck, we are inventing for life. For more than a century, Merck has been inventing medicines and vaccines for many of the world’s most challenging diseases. Today, we’re inventing new ways to help treat cancer, with more than 450 clinical studies underway. Merck is inventing because cancer is one of the world’s most urgent unmet medical needs, with a massive impact both on society and on the lives of individuals. That’s why Merck is investing signifi cant resources to develop innovative oncology medicines. We are taking on the world’s most challenging diseases to help people go on, unburdened, to experience, create and live their best lives. Merck. Inventing for Life. Merck Canada Inc – Proud Silver sponsor of the Canadian Association of Nurses in Oncology conference. Visit us at booth #27. To explore our commitment to invention, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada. Copyright © 2018 Merck Canada Inc., All rights reserved. WHY WE INVENT Congratulations to the nominees of the 2018 At Merck, we are inventing for life. Boehringer Ingelheim Oncology Nurse of the Year Award! Toutes nos félicitations aux candidat(e)s au prix For more than a century, Merck has been inventing medicines and vaccines for many of the world’s most challenging diseases. Boehringer Ingelheim de l'infirmier(ère) de l’année pour 2018! Today, we’re inventing new ways to help treat cancer, with more than 450 clinical studies underway. Janice Dirksen, Vancouver, BC Merck is inventing because cancer is one of the world’s most urgent Lynne Jolicoeur, Ottawa, ON unmet medical needs, with a massive impact both on society and on the lives of individuals. That’s why Merck is investing signifi cant Robin Morash, Carp, ON resources to develop innovative oncology medicines. We are taking Jennifer Newton, Ottawa, ON on the world’s most challenging diseases to help people go on, Joanne Power, Brossard, QC unburdened, to experience, create and live their best lives. Merck.